Hengrui Pharma: Resubmitted Camrelizumab Injection Combination Therapy Application Accepted by FDA

Hengrui Pharma (600276.SH) Resubmits BLA for Camrelizumab Injection, Accepted by FDA

HENGRUI PHARMA (01276): Marketing Authorization Application for HR20013 Injection Accepted by NMPA

Valuation Ranges of Biopharma: Insights from Innovent Biologics, Hengrui Pharmaceuticals, and BeiGene

Zhixintong A-H Statistics | January 30th

Hengrui Pharma (01276) Receives Clinical Trial Approval for HRS-7535 Tablets

HENGRUI PHARMA (01276) Marketing Application for New Indication of Innovative Drug Camrelizumab and Apatinib Combination Accepted

Hengrui Pharma (01276) Repurchases 371,600 A-Shares for RMB 21.074 Million on January 29

Hengrui Pharma (01276) Completes Cumulative Share Buyback of 9.0737 Million Shares by January 27

HENGRUI PHARMA (01276): SHR-1049 Injection Receives Drug Clinical Trial Approval Notice

BRIEF-Citigroup's Long Position In H Shares Of Jiangsu Hengrui Pharmaceuticals Increases To 5.21% On Jan 14 - HKEX

Citigroup's Short Position in H Shares of Jiangsu Hengrui Pharmaceuticals Increases to 5.44% on Jan 14 From 4.81% - HKEX

ZhTong A-H Share Statistics | January 20

FIC/BIC Pipeline Breakthroughs, BD Harvest, and Hong Kong Listing! Hengrui Pharma Poised for Takeoff in 2026

Zhitoing AH Statistics | January 16

Zhixiang A-H Statistics | January 13th

HENGRUI PHARMA (01276): HRS-7535 Tablets Approved for Clinical Trials Targeting Hypertension with Overweight or Obesity

Zhiti AH Statistics | January 12

JPMorgan Increases Stake in Hengrui Pharma by Approx. 1.13 Million Shares at HK$74.61 per Share

JPMorgan Boosts Stake in Hengrui Pharma (01276) by Approximately 1.13 Million Shares at HK$74.61 Per Share